Duloxetine is an SNRI, and tramadol has serotonergic activity. Their combination increases the risk of serotonin syndrome. Agitation, diaphoresis, gastrointestinal symptoms, fever, hyperreflexia, and clonus are characteristic findings. The serotonergic drugs are withheld, the provider or emergency response is notified, and supportive treatment and close monitoring are initiated according to severity.
In-depth explanation
Clinical reasoning
Serotonin syndrome combines mental-status change, autonomic activation, and neuromuscular hyperactivity. Hyperreflexia and clonus strongly distinguish it from anticholinergic toxicity and neuroleptic malignant syndrome.
Decision rule
When duloxetine is combined with another serotonergic drug, treat agitation plus diaphoresis, diarrhea, hyperreflexia, or clonus as a potentially life-threatening serotonergic reaction.
For study reference only. Always follow current clinical guidelines and your institution’s protocols.